US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Perspective Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Participate in Upcoming Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Participate in Upcoming December Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Participate in Upcoming November Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Participate in Upcoming September Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
From Perspective Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >